Short Interest in Evotec SE (NASDAQ:EVO) Decreases By 10.7%

Evotec SE (NASDAQ:EVO) saw a large decrease in short interest in November. As of November 30th, there was short interest totalling 401,600 shares, a decrease of 10.7% from the November 15th total of 449,700 shares. Based on an average trading volume of 197,200 shares, the short-interest ratio is presently 2.0 days. Approximately 0.1% of the shares of the stock are short sold.

Evotec Stock Up 2.4 %

Evotec stock traded up $0.11 during mid-day trading on Tuesday, reaching $4.78. 159,770 shares of the company’s stock were exchanged, compared to its average volume of 132,854. Evotec has a twelve month low of $2.85 and a twelve month high of $12.00. The company has a debt-to-equity ratio of 0.43, a current ratio of 2.09 and a quick ratio of 1.99. The company has a fifty day moving average of $4.22 and a 200-day moving average of $4.14.

Institutional Investors Weigh In On Evotec

A number of hedge funds have recently added to or reduced their stakes in the business. Novo Holdings A S acquired a new stake in shares of Evotec in the 2nd quarter valued at $71,183,000. Wellington Management Group LLP boosted its holdings in shares of Evotec by 29.7% in the third quarter. Wellington Management Group LLP now owns 2,634,434 shares of the company’s stock valued at $9,616,000 after acquiring an additional 602,858 shares in the last quarter. Mediolanum International Funds Ltd acquired a new stake in shares of Evotec in the third quarter valued at about $512,000. DCF Advisers LLC lifted its stake in shares of Evotec by 140.5% in the second quarter. DCF Advisers LLC now owns 114,953 shares of the company’s stock valued at $552,000 after purchasing an additional 67,156 shares during the period. Finally, Clear Harbor Asset Management LLC acquired a new stake in shares of Evotec in the third quarter valued at about $104,000. 5.81% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several analysts have recently weighed in on the stock. Jefferies Financial Group cut shares of Evotec from a “buy” rating to a “hold” rating and dropped their price target for the company from $8.70 to $3.80 in a research note on Monday, October 7th. HC Wainwright reaffirmed a “buy” rating and set a $8.00 price objective on shares of Evotec in a research report on Thursday, November 7th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and two have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $5.93.

About Evotec

Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women’s health.